ClearPoint Neuro Announces FDA Clearance for Software Version 2.1
September 19, 2022 16:13 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Reports Second Quarter 2022 Results
August 09, 2022 16:15 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model
August 09, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs
August 08, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022
July 26, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro beglückwünscht Partner PTC Therapeutics für den Erhalt der Marktzulassung durch die Europäische Kommission für Upstaza™ - die erste krankheitsmodifizierende Behandlung von AADC-Mangel
July 22, 2022 12:22 ET
|
ClearPoint Neuro, Inc.
Die erste zur direkten Infusion in das Gehirn zugelassene Gentherapie wird mit der SmartFlow® Neurokanüle von ClearPoint verabreicht SOLANA BEACH, Kalifornien, July 22, 2022 (GLOBE NEWSWIRE) --...
ClearPoint Neuro félicite son partenaire PTC Therapeutics pour l'obtention de l'autorisation de mise sur le marché par la Commission européenne pour Upstaza™ - premier traitement modificateur de la maladie pour le déficit en AADC
July 22, 2022 12:22 ET
|
ClearPoint Neuro, Inc.
La première thérapie génique approuvée pour une perfusion directe dans le cerveau sera administrée avec la canule neurologique SmartFlow® de ClearPoint SOLANA BEACH, Californie, 22 juill. 2022 ...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency
July 21, 2022 16:20 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
June 29, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces Receipt of MDSAP Certification
June 02, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...